Complex | |
AACDB_ID: | 1003 |
PDBID: | 4UU9 |
Chains: | AB_C |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.12 |
Reference: | 10.1080/19420862.2017.1384892 |
Antibody | |
Antibody: | MEDI7814 Fv |
Antibody mutation: | No |
INN (Clinical Trial): | |
Antigen | |
Antigen: | COMPLEMENT C5 |
Antigen mutation: | No |
Durg Target: | P01031 |
Antibody
Heavy Chain: A
Mutation: NULL
>4UU9_A|Chain A, E[auth H]|MEDI7814|HOMO SAPIENS (9606) EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDDYEEWPWYYGMDVWGQGTMVTVS |
Light Chain: B
Mutation: NULL
>4UU9_B|Chain B, F[auth L]|MEDI7814|HOMO SAPIENS (9606) QSALTQPASVSGSPGQSITISCTGTSSDIGGSKYVSWYQQHPGKAPKLIIFDVNRRPSGLSNRFSASKSGNTASLTISGLQAEDEADYYCTSYHPTKTILFGGGTKLTVLA |
Antigen
Chain: C
Mutation: NULL
>4UU9_C|Chain C, D|COMPLEMENT C5|HOMO SAPIENS (9606) STLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGR |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
A: SER31 TYR32 ARG94 ASP95 ASP96 ASP97 ASP101 VAL102 B: LYS31 TYR32 LEU46 ILE48 PHE49 ASP50 VAL51 ASN52 ARG53 ALA64 C: LYS14 HIS15 SER16 VAL17 VAL18 LYS19 LYS20 CYS21 ASP24 CYS27 GLU32 ARG37 ARG40 ILE41 SER42 LEU43 GLY44 PRO45 ARG46 CYS47 PHE51 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)